Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise

Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise Soumya Eswaran Mon, May 11, 2026 at 8:13 PM GMT+7 3 min read EW Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. A copy of the letter is available to download here. In Q1 2026, the Artisan Mid Cap Fund reported negative absolute returns but slightly outperformed the Russell Midcap® Growth Index. The market favored lower volatility and income-oriented equities, with value outpacing growth significantly. Despite challenges for growth strategies, selective stock choices in sectors like industrials and healthcare provided strength, while consumer discretionary faced weaknesses. Mid- and small-cap indices showed resilience amid lagging large-cap growth stocks. The escalating conflict in Iran influenced market behavior, and AI-related investments continued to support capital spending and earnings. In addition, please check the Fund’s top five holdings to know its best picks in 2026.

In its first-quarter 2026 investor letter, Artisan Mid Cap Fund highlighted stocks like Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) is a leading medical technology company specializing in the treatment of advanced cardiovascular diseases. On May 8, 2026, Edwards Lifesciences Corporation (NYSE:EW) closed at $79.96 per share. One-month return of Edwards Lifesciences Corporation (NYSE:EW) was 2.36%, and its shares gained 6.90% over the past 52 weeks. Edwards Lifesciences Corporation (NYSE:EW) has a market capitalization of $46.04 billion.

Artisan Mid Cap Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its Q1 2026 investor letter: